Table 1.
Patients, disease, graft and conditioning.
| N | 59 |
| Median age (range) | 63 (18–72) |
| Male/female | 28/31 |
| Median weight (range) | 73 (41–136) |
| Disease | |
| MDS/AML vs. ALL vs. lymphoma vs. othera | 39-6-11-3 |
| Haplo-graft | |
| HLA match with host 4–5/8 vs. 6–7/8 | 53 vs. 6 |
| HLA match with UCB 1–4/8 vs. 5–7/8 | 54 vs. 5 |
| DSA present against haplo | 6 |
| UCB graft | |
| CD34 dose collected median-range (×105/kg) | 0.86 (0.13–4.3) |
| CBU viability at infusion (Trypan Blue) (range) | 97% (87–100) |
| TNC infused (×107 kg) (range) | 2.0 (0.2–8.2) |
| HLA match with host 4-5-6/8 vs. 7–8/8 | 35 vs. 24 |
| DSA present against UCB | 7 |
| Flu Mel ATG vs. Flu MEL ATG low dose TBI | 45 vs. 14 |
a
Other: one case of severe aplastic anemia, two cases of chronic lymphocytic leukemia.
AML: acute myeloid leukaemia; CBU: Cord blood unit; DSA: donor specific antibodies; HLA: human leukocyte antigen; MDS: myelodysplastic syndrome; TNC: total nucleated cells; UCB: umbilical cord blood.